Eikon Therapeutics is a biopharmaceutical company transforming drug discovery with advanced live-cell resolution microscopy and engineering innovations. Using single-molecule imaging technology, Eikon enables real-time observation of molecular interactions, offering unparalleled insights into disease biology. This cutting-edge approach helps researchers identify and optimize drug candidates more efficiently, reducing time and costs in early-stage drug development. With a strong focus on innovation, Eikon is advancing the future of precision medicine by unlocking new therapeutic possibilities.
Eikon Therapeutics has raised $350.7 million in a Series D funding round to fund a rapidly expanding clinical pipeline of cancer therapies. In total, the company has raised about $1.1 billion to date.
Eikon Therapeutics, Hayward, California, United States, was founded in 2019 by Eric Betzig, Luke Lavi, Robert Tjian, and Xavier Darzacq. Eikon Therapeutics operates in the biopharmaceutical and biotechnology markets, focusing on drug discovery and development through advanced live-cell imaging and AI-driven analysis. Its innovations primarily impact the pharmaceutical R&D sector, with applications in oncology, neurology, and precision medicine across global healthcare markets. With its groundbreaking technology and strong financial backing, Eikon Therapeutics is well-positioned to drive the future of drug discovery and advance transformative treatments for patients worldwide.
Share this post